Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infections in Spain: SMART 2003 study outcomes;Patrones de sensibilidad a antimicrobianos de Enterobacteriaceae causantes de infecciones intraabdominales en España: Resultados del estudio SMART 2003

Revista Espanola de Quimioterapia

Volumn 19, Issue 1, 2006, Pages 51-59

  Baquero, F ^a   Cercenado, E ^b   Cisterna, R ^c   De La Rosa, M ^d   Garcia Rodriguez J A ^e   Gobernado, M ^f   Perez J L ^g   Manchado, P ^h   Martin R ⁱ   Pascual, A ^j   Picazo, J ^k   Prats, G ^l   Rubio, C ^m   Snyder, T A ⁿ   Sanz Rodriguez C ^o  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

^o Medical affairs Merck sharp and Dohme ltd   (Spain)

more..

Author keywords

Carbapenems; Enterobacteriaceae; Ertapenem; Extended spectrum beta lactamases

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTER; ESCHERICHIA COLI; KLEBSIELLA; NONHUMAN; PHENOTYPE; PROTEUS; SPAIN;

ABDOMEN; ABDOMINAL ABSCESS; ABDOMINAL INJURIES; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FECES; HUMANS; MICROBIAL SENSITIVITY TESTS; PERITONITIS; SPAIN; WORLD HEALTH;

EID: 33744755662     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Felmingham, D., Grüneberg, R.N. A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother 1996; 38 (Suppl. A): 1-57.
2. Pfaller, M.A., Jones, R.N., Doeni, G.V. y cols. Bacterial pathogens isolated from patients with bloodstream injection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Chemother 1998; 42: 1762-1770.
3. Turner, P.J., Greenhalgh, J.M., Edwards, J.R. y cols. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int J Antimicrob Agents 1999; 13: 117-125.
4. Jones, R.N., Masterton, R. Determining the value of antimicrobial surveillance programs. Diagn Microbiol Infect Dis 2001; 41: 171-175.
5. Felmingham, D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 (Suppl. S1): 1-7.
6. Paterson, D.L., Rossi, F., Baquero, F. y cols. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 965-973.
7. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 6th ed. Approved Standard M7-A6. NCCLS, Villanova, PA, USA, 2003.
8. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, 13th Informational Supplement. Supplemental Tables M100-S13. NCCLS, Villanova, PA, USA, 2003.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement. M100-S15, Vol. 25 , No. 1. CLSI, Wayne, PA, USA, 2005.
10. Stürenburg, E., Sobottka, I., Noor, D. y cols. Evaluation of a cefepime-clavulanate ESBL E-test to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother 2004; 54: 134-138.
11. Cornaglia, G., Hryniewicz, W., Jarlier, V. y cols. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349-383.
12. Karlowsky, J.A., Jones, M.E., Thornsberry, C. y cols. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1672-1680.
13. Wenzel, R.P., Sahm, D.F., Thornsberry, C. y cols. In vitro susceptibilities of Gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: Implications for therapy. Antimicrob Agents Chemother 2003; 47: 3089-3098.
14. Livermore, D.M. The threat from the pink corner. Ann Med 2003; 35: 226-234.
15. Tortola, M.T., Lavilla S., Miró, E. y cols. First detection of a carbapenem-hydrolyzing metalloenzyme in two enlerobacteriaceae isolates in Spain. Antimicrob Agents Chemother 2005; 49: 3492-3494.
16. Livermore, D.M., Woodford, N. Carbapenemases: A problem in waiting? Curr Opin Microbiol 2000; 3: 489-495.
17. Bradford, P.A., Urban, C., Mariano, N. y cols. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-569.
18. Yan, J.J., Ko, W.C., Chuang, C.L. y cols. Metallo-beta-lactamase- producing Enterobacteriaceae isolates in a university hospital in Taiwan: Prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J Chemother 2002; 50: 503-511.
19. Livermore, D.M., Sefton, A.M., Scott, G.M. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-344.
20. Schmitz, F.J., Verhoef, J., Fluit, A.C. y cols. Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 1999; 18: 414-421.
21. Dornbusch, K., Miller, G.H., Hare, R.S. y cols. Resistance to aminoglycoside antibiotics in Gram-negative bacilli and staphylococci isolated from blood. Report from a European collaborative study. J Antimicrob Chemother 1990; 26: 131-144.
22. European Study Group on Antibiotic Resistance. In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratories. Eur J Clin Microbiol 1987; 6: 378-385.
23. Cox, J.R., McKay, G.A., Wright, G.D. y cols. Arrangement of substrates at the active site of an aminoglycoside antibiotic 3′-phosphotransferase as determined by NMR. J Am Chem Soc 1996; 118: 1295-1301.
24. Mazuski, J.E., Sawyer, R.G., Nathens, A.B. y cols. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002; 3: 161-173.
25. Solomkin, J.S., Mazuski, J.E., Baron, E.J. y cols. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
26. Tellado, J.M., Sitges-Serra, A., Barcenilla, F. y cols. Pautas de tratamiento antibiótico empírico de las infecciones intraabdominales. Rev Esp Quimioterap 2005; 18: 179-186.
27. Stürenburg, E., Mack, D. Extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47: 273-295.
28. Valverde, A., Coque, T.M., Sánchez-Moreno, M.P. y cols. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-4775.
29. Sorlozano, A., Gutiérrez, J., Palanca, M. y cols. High incidence of extended-spectrum beta-lactamases among outpatient clinical isolates of Escherichia coli: A phenotypic assessment of NCCLS guidelines and a commercial method. Diagn Microbiol Infect Dis 2004; 50: 131-134.
30. Rodríguez-Baño, J., Navarro, M.D., Romero, L. y cols. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
31. Daza, R., Gutiérrez, J., Piédrola, G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-215.
32. Hernández, J.R., Pascual, A., Cantón, R. y cols. Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21: 77-82.
33. Hernández, J.R., Martínez-Martínez, L., Cantón, R. y cols. Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain. Antimicrob Agents Chemother 2005; 49: 2122-2125.
34. Borer, A., Gilad, J., Menashe, G. y cols. Extended-spectrum beta-lactamase-producing Emerobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med Sci Monit 2002; 8: CR44-CR47.
35. Cormican, M., Morris, D., Corbett-Feeney G. y cols. Extended-spectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community-acquired urinary tract infection. Diagn Microbiol Infect Dis 1998; 32: 317-319.
36. Goldstein, F.W., Multicenter Study Group. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 2000; 19: 112-117.
37. Hryniewicz, K., Szczypa, K., Sulikowska, A. y cols. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-780.
38. Lescure, F.X., Eveillard, M., Douadi, Y. y cols. Community-acquired multiresistant bacteria: An emerging problem? J Hosp Infect 2001; 49: 149-151.
39. Pitout, J.D., Nordmann, P., Laupland, K.B. y cols. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
40. Paterson, D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-463.
41. Essack, S.Y. Treatment options for extended-spectrum beta-lactamase- producers. FEBS Microbiol Lett 2000; 190: 181-184.
42. Livermore, D.M., Woodford, N. Guidance to diagnostic laboratories: Laboratory detection and reporting of bacteria with extended-spectrum beta-lactamases. Health Protection Agency, Londres, Reino Unido 2004. Accessed on 13 September 2005 at: http://www.hpa.org. uk/srmd/div_nsi_armrl/ ESBL_advice_June_2004.pdf
43. Livermore, D.M., Mushtaq, S., Warner, M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55: 306-311.
44. Livermore, D.M. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.